Table 1 Baseline characteristics of study participants in the training and validation set
Variable | Training set | Validation set | P | ||
|---|---|---|---|---|---|
No. | % | No. | % | ||
Control group count | 24 | 44 | |||
Age, years | |||||
≤50 | 13 | 54.17 | 25 | 56.82 | 0.833 |
>50 | 11 | 45.83 | 19 | 43.18 | |
Menstruation | |||||
Pre-menopause | 13 | 54.17 | 25 | 56.82 | 0.833 |
Post-menopause | 11 | 45.83 | 19 | 43.18 | |
Breast cancer group count | 24 | 58 | |||
Age, years | |||||
≤50 | 13 | 54.17 | 27 | 46.55 | 0.53 |
>50 | 11 | 45.83 | 31 | 53.45 | |
Menstruation | |||||
Pre-menopause | 13 | 54.17 | 29 | 50 | 0.731 |
Post-menopause | 11 | 45.83 | 29 | 50 | |
Histologic tumor size (cm) | |||||
≤2 | 9 | 37.5 | 23 | 39.66 | 0.711 |
2–5 | 12 | 50 | 31 | 53.45 | |
>5 | 3 | 12.5 | 4 | 6.89 | |
Lymph nodes | |||||
Positive | 16 | 66.67 | 30 | 51.72 | 0.215 |
Negative | 8 | 33.33 | 28 | 48.28 | |
Estrogen receptors | |||||
Positive | 14 | 58.33 | 29 | 50 | 0.492 |
Negative | 10 | 41.67 | 29 | 50 | |
Progestogen receptors | |||||
Positive | 14 | 58.33 | 29 | 50 | 0.492 |
Negative | 10 | 41.67 | 29 | 50 | |
HER2 status | |||||
Positive | 12 | 50 | 24 | 41.38 | 0.474 |
Negative | 12 | 50 | 34 | 58.62 | |
Ki67 labeling index | |||||
≤14 | 1 | 4.17 | 6 | 10.34 | 0.362 |
>14 | 23 | 95.83 | 52 | 89.66 | |
Histological grade | |||||
1 | 0 | 0 | 0 | 0 | 0.097 |
2 | 8 | 33.33 | 31 | 53.45 | |
3 | 16 | 66.67 | 27 | 46.55 | |
